Innovative Bispecific Nanobody Targeting ALB and ERBB2 for Cancer Immunotherapy

VHH-P457 is a novel humanized multispecific nanobody designed to target both albumin (ALB) and erb-b2 receptor tyrosine kinase 2 (ERBB2). Currently in the Biological Testing stage, this program represents an advanced approach for cancer treatment. By engaging two critical molecular targets—albumin (a key plasma protein) and ERBB2 (a well-validated oncogenic driver)—VHH-P457 aims to improve therapeutic selectivity and efficacy in oncological indications. The unique structural design of VHH-P457 enables versatile application in cancer, positioning it at the forefront of nanobody-based immuno-oncology development.

Licensing Opportunity

VHH-P457 is actively open for out-licensing and collaborative development opportunities. We welcome industry partners to join forces in advancing this innovative program towards clinical and commercial success in cancer immunotherapy.

Development Phase

Modality

VHH-P457 adopts a novel multispecific T cell engager prodrug architecture, comprised of tandemly fused single-domain antigen-binding domains against human ERBB2 and ALB, alongside anti-CD3 and anti-CD28 scFvs, a matrix metalloproteinase-9 cleavage site, and an NCL linker. The nanobody’s small molecular size and single-domain structure confer superior tissue penetration, stability, and modularity, features especially advantageous in targeting heterogenous tumors. This architecture facilitates precise immune cell recruitment and tumor-specific activation, optimizing anti-cancer responses while reducing systemic toxicity. The inherent flexibility of the nanobody format further permits rational engineering for tailored cancer therapies.

Target

ALB and ERBB2 are pivotal molecular targets for innovative cancer therapies. ALB, as a plasma protein, functions in molecule transport and regulates oncotic pressure, highly expressed in the bloodstream and specific tissues. ERBB2, a transmembrane tyrosine kinase receptor of the EGFR family, is most notably overexpressed in various aggressive cancers, including breast and gastric malignancies. Targeting both ALB and ERBB2 combines the benefits of extended serum half-life (via ALB) and potent anti-tumor activity (via ERBB2). VHH-P457’s ability to engage both ALB and ERBB2 offers strategic advantages, allowing enhanced drug delivery, improved pharmacokinetics, and precise tumor cell targeting. Dual targeting of ALB and ERBB2 positions VHH-P457 as a promising asset in the evolving landscape of cancer biologics.

Mechanism of Action

VHH-P457 exerts its therapeutic effects through multispecific engagement of ALB and ERBB2. By binding ALB, VHH-P457 achieves prolonged systemic circulation, optimizing exposure and therapeutic window. Targeting ERBB2 enables direct recognition of tumor cells, while incorporated anti-CD3 and anti-CD28 scFvs recruit and activate T cells, initiating potent cytotoxic responses against ERBB2-positive malignancies. The inclusion of a protease-cleavable linker enhances tumor selectivity, restricting T cell engagement to the tumor microenvironment. This platform’s modular nature allows broad application, supporting the future development of antibody-drug conjugates or bispecific and trispecific constructs for expanded oncology indications.

Cancer

Cancer remains one of the most prevalent and challenging diseases globally, with rising incidence and mortality across diverse populations. Conventional treatment approaches include surgery, radiation, chemotherapy, and hormonal therapy, complemented in recent years by targeted therapy and immunotherapy. While these modalities have improved survival for certain cancers, many patients encounter relapse, resistance, or intolerable adverse effects. Current unmet needs include improving tumor specificity, reducing systemic toxicity, and overcoming immune escape mechanisms. Nanobody-based agents such as VHH-P457, which combine immune cell engagement with dual targeting, represent a promising evolution in cancer therapeutics. Their potential for improved tissue penetration and selective immune activation offers new hope in addressing refractory and aggressive cancers where standard care is insufficient.